Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Vitamin B3 and Reduced pTau231 Level

Doses used in studies

mg/day: 1,500 (median 1,500, IQR 1,500–1,500) — 1 study

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
While nicotinamide demonstrated good safety and tolerability
from: Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical t

1 of 1 paper

Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer's disease.
- 2025-03-11
- RCT · n = 23
- Alzheimer's research & therapy 17(1)
- - Gabriel L Ketron
  - Felix Grun
  - Joshua D Grill
  - Howard H Feldman
  - Robert A Rissman
  - Gregory J Brewer
- PubMed: 40069789
- DOI: 10.1186/s13195-025-01693-y
1 Insight on
- Reduced pTau231 Level
- High evidence
- Clinical
Treatment favorably decreased mean pTau231 levels... compared to 3% elevation in participants who did not have elevated CSF nicotinamide, and a 3% decrease for placebo
Effect
Neutral
Effect size
Small
Significant
No
Dose
1500 mg PO BID